Sebastian Camillo Holst

Sebastian Camillo Holst

orcid

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 February 2022 in Brain
Verified
Journal Article
Open access
PDF file
EBEmily Eufaula Beaman
Emily Eufaula Beaman
ABAnders Nissen Bonde
Anders Nissen Bonde
SLSara Marie Ulv Larsen
Sara Marie Ulv Larsen
BOBrice Ozenne
Brice Ozenne
TLTerhi Johanna Lohela
Terhi Johanna Lohela
SHSebastian Camillo Holst
Sebastian Camillo Holst
Alzheimer's disease is a neurodegenerative disorder in which the pathological accumulation of amyloid-β and tau begins years before symptom onset. Emerging evidence suggests that β-blockers (β-adrenergic antagonists) increase brain clearance of these metabolites by enhancing CSF flow. Our objective was to determine whether β-blocker treatments that easily cross the blood–brain barrier reduce the risk of Alzheimer's disease compared to less permeable β-blockers. Data from the Danish national registers were used to identify a retrospective cohort of individuals with hypertension, and those treated with β-blockers were included in the analysis. People with indications for β-blocker use other than hypertension (e.g. heart failure) were only retained in a sensitivity analysis. β-blockers were divided into three permeability groups: low, moderate and high. We used multivariable cause-specific Cox regression to model the effect of β-blocker blood–brain barrier permeability on time to dementia outcomes, adjusting for baseline comorbidities, demographics and socioeconomic variables. Death was modelled as a competing risk. The 10-year standardized absolute risk was estimated as the averaged person-specific risks per treatment. In a cohort of 69 081 (median age = 64.4 years, 64.8% female) people treated with β-blockers for hypertension, highly blood–brain barrier-permeable β-blockers were associated with reduced risk of Alzheimer's disease versus low permeability β-blockers (−0.45%, P < 0.036). This effect was specific to Alzheimer's diagnoses and did not extend to dementia in general. Propensity score analysis matching high and low blood–brain barrier-permeable patients also detected a decreased Alzheimer's risk (−0.92%, P < 0.001) in the high permeability group compared to the low, as did a 1-year landmark analysis (−0.57%, P < 0.029) in which events within the first year of follow-up were ignored as likely unrelated to treatment. Our results suggest that amongst people taking β-blockers for hypertension, treatment with highly blood–brain barrier permeable β-blockers reduces the risk of Alzheimer's disease compared to low permeability drugs. Our findings support the hypothesis that highly permeable β-blockers protect against Alzheimer's disease by promoting waste brain metabolite clearance.

31 March 2021 in Brain
Verified
Journal Article
Open access
PDF file
ZRZalán Rajna
Zalán Rajna
HMHeli Mattila
Heli Mattila
NHNiko Huotari
Niko Huotari
TTTimo Tuovinen
Timo Tuovinen
JKJohanna Krüger
Johanna Krüger
VKVesa Kiviniemi
Vesa Kiviniemi
Accumulation of amyloid-β is a key neuropathological feature in brain of Alzheimer’s disease patients. Alterations in cerebral haemodynamics, such as arterial impulse propagation driving the (peri)vascular CSF flux, predict future Alzheimer’s disease progression. We now present a non-invasive method to quantify the three-dimensional propagation of cardiovascular impulses in human brain using ultrafast 10 Hz magnetic resonance encephalography. This technique revealed spatio-temporal abnormalities in impulse propagation in Alzheimer’s disease. The arrival latency and propagation speed both differed in patients with Alzheimer’s disease. Our mapping of arterial territories revealed Alzheimer’s disease-specific modifications, including reversed impulse propagation around the hippocampi and in parietal cortical areas. The findings imply that pervasive abnormality in (peri)vascular CSF impulse propagation compromises vascular impulse propagation and subsequently glymphatic brain clearance of amyloid-β in Alzheimer’s disease.

1 January 2013 in Biological Psychiatry
Verified
Journal Article
Closed access
KHKatharina Hefti
Katharina Hefti
SHSebastian Camillo Holst
Sebastian Camillo Holst
JSJudit Sovago
Judit Sovago
VBValérie Bachmann
Valérie Bachmann
ABAlfred Buck
Alfred Buck
Hans-Peter LandoltHans-Peter Landolt
Hans-Peter Landolt

1 June 2018 in Sleep Medicine Clinics
Verified
Journal Article
Closed access
SHSebastian Camillo Holst
Sebastian Camillo Holst
Hans-Peter LandoltHans-Peter Landolt
Hans-Peter Landolt

5 October 2017 in eLife
Verified
Journal Article
Open access
SHSebastian Camillo Holst
Sebastian Camillo Holst
ASAlexandra Sousek
Alexandra Sousek
KHKatharina Hefti
Katharina Hefti
SSSohrab Saberi-Moghadam
Sohrab Saberi-Moghadam
ABAlfred Buck
Alfred Buck
Hans-Peter LandoltHans-Peter Landolt
Hans-Peter Landolt
Increased sleep time and intensity quantified as low-frequency brain electrical activity after sleep loss demonstrate that sleep need is homeostatically regulated, yet the underlying molecular mechanisms remain elusive. We here demonstrate that metabotropic glutamate receptors of subtype 5 (mGluR5) contribute to the molecular machinery governing sleep-wake homeostasis. Using positron emission tomography, magnetic resonance spectroscopy, and electroencephalography in humans, we find that increased mGluR5 availability after sleep loss tightly correlates with behavioral and electroencephalographic biomarkers of elevated sleep need. These changes are associated with altered cortical myo-inositol and glycine levels, suggesting sleep loss-induced modifications downstream of mGluR5 signaling. Knock-out mice without functional mGluR5 exhibit severe dysregulation of sleep-wake homeostasis, including lack of recovery sleep and impaired behavioral adjustment to a novel task after sleep deprivation. The data suggest that mGluR5 contribute to the brain's coping mechanisms with sleep deprivation and point to a novel target to improve disturbed wakefulness and sleep.

8 January 2014 in Journal of Neuroscience
Verified
Journal Article
Open access
PDF file
SHSebastian Camillo Holst
Sebastian Camillo Holst
ABAlessia Bersagliere
Alessia Bersagliere
VBValérie Bachmann
Valérie Bachmann
WBWolfgang Berger
Wolfgang Berger
PAPeter Achermann
Peter Achermann
Hans-Peter LandoltHans-Peter Landolt
Hans-Peter Landolt
While dopamine affects fundamental brain processes such as movement control, emotional responses, addiction, and pain, the roles for this neurotransmitter in regulating wakefulness and sleep are incompletely understood. Genetically modified animal models with reduced dopamine clearance exhibit hypersensitivity to caffeine, reduced-responsiveness to modafinil, and increased homeostatic response to prolonged wakefulness when compared with wild-type animals. Here we studied sleep–wake regulation in humans and combined pharmacogenetic and neurophysiologic methods to analyze the effects of the 3′-UTR variable-number-tandem-repeat polymorphism of the gene (DAT1,SLC6A3) encoding dopamine transporter (DAT). Previous research demonstrated that healthy homozygous 10-repeat (10R/10R) allele carriers of this genetic variant have reduced striatal DAT protein expression when compared with 9-repeat (9R) allele carriers. Objective and subjective estimates of caffeine sensitivity were higher in 10R allele homozygotes than in carriers of the 9R allele. Moreover, caffeine and modafinil affected wakefulness-induced changes in functional bands (delta, sigma, beta) of rhythmic brain activity in wakefulness and sleep in aDAT1genotype-dependent manner. Finally, the sleep deprivation-induced increase in well established neurophysiologic markers of sleep homeostasis, including slow-wave sleep, electroencephalographic slow-wave activity (0.5–4.5 Hz), and number of low-frequency (0.5–2.0 Hz) oscillations in non-rapid-eye-movement sleep, was significantly larger in the 10R/10R genotype than in the 9R allele carriers ofDAT1. Together, the data suggest that the dopamine transporter contributes to homeostatic sleep–wake regulation in humans.